Review: Clinical Trial Outcomes For reprint orders, please contact
[email protected] 4 Review: Clinical Trial Outcomes Rupatadine for the treatment of allergic rhinitis and urticaria: a look at the clinical data Clin. Invest. The second-generation antihistamine rupatadine is a new long-acting and Erminia Ridolo*,1, Marcello non-sedating drug that exerts a potent dual-antagonist activity towards the histamine Montagni1, Filippo Fassio2, H1 receptor and the PAF receptor. Rupatadine is prescribed for the relief of symptoms Ilaria Massaro3, Oliviero 4 5 of seasonal and perennial allergic rhinitis and in the treatment of chronic urticaria. Rossi , Cristoforo Incorvaia & Giorgio Walter Canonica6 Clinical trials have shown that rupatadine, which shows a rapid onset of action and 1Department of Clinical & Experimental prolonged duration of activity, is effective and well tolerated. Safety data indicate Medicine, University of Parma, Parma, Italy that rupatadine does not affect the cardiovascular system, without relevant changes 2Department of Biomedicine, Immunology in the corrected QT interval, or significantly affect psychomotor activity at the doses & Cell Therapies Unit, AOU Careggi, used in clinical practice. Here, we review the efficacy and safety profile of rupatadine University of Florence, Italy 3 in patients with allergic rhinitis and urticaria. Centre for Research, Transfer & High Education DENOTHE, University of Florence, Florence, Italy Keywords: allergic rhinitis • chronic urticaria • histamine • platelet-activating factor 4Department of Biomedicine, • rupatadine Immunoallergology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy The new antihistamine rupatadine is a potent, distinct clinical entities both respond to anti- 5Pulmonary Rehabilitation Unit, ICP orally active, non-sedating, long-acting antag- histamine treatment. This review focuses on Hospital, Milan, Italy onist of both histamine H1 receptors and PAF the clinical characteristics of rupatadine and 6Allergy & Respiratory Diseases Clinic, receptors.